MAB038
Anti-Factor VIII Antibody, 83 kDa light chain
ascites fluid, Chemicon®
Synonym(s):
Coagulant Component, Antihemophilic Factor, AHF
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
biological source
mouse
Quality Level
antibody form
ascites fluid
antibody product type
primary antibodies
clone
monoclonal
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
ELISA: suitable
western blot: suitable
isotype
IgG2a
NCBI accession no.
UniProt accession no.
shipped in
dry ice
target post-translational modification
unmodified
Gene Information
human ... F8(302470) , F8(2157)
Specificity
By Western blot the antibody recognizes the 83 kDa light chain of human Factor VIII. No cross reactivity with von Willebrand factor.
Immunogen
Epitope: 83 kDa light chain
Purified Human Factor VIII.
Application
Anti-Factor VIII Antibody, 83 kDa light chain is an antibody against Factor VIII for use in ELISA & WB.
ELISA (indirect): 1:16,000.
Western blotting: Factor VIII makes up only about 1% of the ciruculating FactorVIII/vWF complex with the bulk of the complex being vWF (99% by mass, see Blood 58:1-13, 1981). Thus it is recommended that the FactorVII/vWF be precipitated out of plasma prior to detection of Factor VII with MAB038. Also, when blotting plasma preparations, background, non-specific bands, caused by the serum proteins are common. More complex blocking solutions or higher salt concentrations can help remove non-specific bands. Rotblat, et al (1985) Biochemistry 24(16):4294-4300. Should be consulted for additional tips with regard to detecting Factor VII via westerns.
Optimal working dilutions must be determined by the end user.
Western blotting: Factor VIII makes up only about 1% of the ciruculating FactorVIII/vWF complex with the bulk of the complex being vWF (99% by mass, see Blood 58:1-13, 1981). Thus it is recommended that the FactorVII/vWF be precipitated out of plasma prior to detection of Factor VII with MAB038. Also, when blotting plasma preparations, background, non-specific bands, caused by the serum proteins are common. More complex blocking solutions or higher salt concentrations can help remove non-specific bands. Rotblat, et al (1985) Biochemistry 24(16):4294-4300. Should be consulted for additional tips with regard to detecting Factor VII via westerns.
Optimal working dilutions must be determined by the end user.
Research Category
Inflammation & Immunology
Inflammation & Immunology
Research Sub Category
Immunoglobulins & Immunology
Immunoglobulins & Immunology
Physical form
Liquid. Contains no preservative.
Storage and Stability
Maintain at -20°C in undiluted aliquots for up to 12 months from date of receipt. Avoid repeated freeze/thaw cycles.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
WGK
WGK 2
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Haarin Chun et al.
Journal of thrombosis and haemostasis : JTH, 19(4), 954-966 (2021-02-03)
Therapeutic products with coagulation factor VIII (FVIII) have a wide range of specific activities, implying presence of protein with altered structure. Previous studies showed that recombinant FVIII products (rFVIII) contain a fraction (FVIIIFT ) unable to bind von Willebrand factor
M Arai et al.
Proceedings of the National Academy of Sciences of the United States of America, 86(11), 4277-4281 (1989-06-01)
An immunoadsorbent method has been developed for the direct analysis of normal and variant plasma factor VIII. Using this method, the molecular defect responsible for mild hemophilia A has been identified for a patient whose plasma factor VIII activity is
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service